COMMUNIQUÉS West-GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/04/2025
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven [...]
TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2024 Financial Results
14/04/2025
FREDERICK, Md., April 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization [...]
Voting Rights and Shares Capital of the Company
14/04/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 14, 2025 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
14/04/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 avr. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
14/04/2025
Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, [...]
SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025
14/04/2025
SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first [...]
Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock
14/04/2025
TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced [...]
Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
14/04/2025
MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
NeuroPace Provides Update on Tariff Status
14/04/2025
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. ( [...]
Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results
14/04/2025
KIRKLAND, Wash., April 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today reported financial results for the third [...]
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
14/04/2025
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and [...]
IBA – ACQUISITION OF OWN SHARES
14/04/2025
Immediate Release – April 14 th , 2025 Louvain-la-Neuve, Belgium, April 14 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
IBA – ACQUISITION D’ACTIONS PROPRES
14/04/2025
Publication immédiate – 14 avril 2025 Louvain-la-Neuve, Belgique, 14 avril 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
14/04/2025
WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio [...]
Epilepsy Community Unites to Oppose Cuts to Crucial Federal Epilepsy Programs
14/04/2025
BOWIE, Md., April 14, 2025 (GLOBE NEWSWIRE) -- The 118 undersigned organizations – representing people living with epilepsy; caregivers and loved ones; physicians, care providers, and epilepsy centers; epilepsy [...]
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
14/04/2025
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “ [...]
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
14/04/2025
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 [...]
AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose
14/04/2025
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET AMERICAIN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE Paris, 14 avril 2025, 18h AB Science SA (Euronext - [...]
Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
14/04/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Pages